ASCO: Vepdegestrant ups survival in ER+, HER2− advanced breast cancer with ESR1 mutations

Published Date: 03 Jun 2025

For patients with estrogen receptor (ER)-positive, human epidermal growth factor receptor 2 (HER2)-negative advanced breast cancer, the oral proteolysis-targeting chimera ER degrader, vepdegestrant, leads to significantly ...

Read Full News

Latest News


News All Time

Featured News
Featured Articles
Featured Events
Featured KOL Videos

1.

Did U.S. Government Play a Role in Remote Tribe's Widespread Illness and Cancer?

2.

Nuclear missile workers are contracting cancer: They blame the bases

3.

Getting Lung Cancer Screening Staff Involved Improved Tobacco Cessation

4.

'Significant Milestone' for Radionuclide Therapy in Refractory Meningioma

5.

Through the activation of bitter taste receptors, lidocaine has the potential to kill some cancer cells.


© Copyright 2026 Hidoc Dr. Inc.

Terms & Conditions - LLP | Inc. | Privacy Policy - LLP | Inc. | Account Deactivation
bot